SAN FRANCISCO, August 06, 2025--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the enrollment of the first participant in ECLIPSE 3. All three trials in the Company’s registrational ...

All three trials in the Company’s registrational ECLIPSE program for chronic hepatitis delta (CHD) have now been initiated.

ECLIPSE is a registrational program to evaluate the safety and efficacy of tobevibart in combination with elebsiran in patients with chronic hepatitis delta (CHD).

"Should be overturned." First-of-its-kind lawsuit seeks to reverse sudden slashing of $3B program: 'Arbitrary and capricious' first appeared on The Cool Down.

According to the TIOBE Programming Community index, the following are the top 10 programming languages in August 2025. Python: A general-purpose programming language commonly used for back-end ...